AZENTA, INC.
AZTA US1143401024
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 56% | -44% | 11% | -23% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Marotta John CEO |
29.41 USD |
316 Sold |
9,294 USD |
09/09/2025 | 10/09/2025 |
| Lin Lawrence Y. CFO |
27.96 USD |
2,500 Bought |
69,900 USD |
11/08/2025 | 11/08/2025 |
| Hughes Violetta CCO |
52.97 USD |
317 Sold |
16,791 USD |
03/02/2025 | 03/02/2025 |
| Zhou Ginger VP |
45.88 USD |
417 Bought |
19,132 USD |
31/01/2025 | 31/01/2025 |
| Wang David Dong VP |
46.65 USD |
140 Sold |
6,531 USD |
04/12/2024 | 04/12/2024 |
| Marotta John CEO |
40.67 USD |
1,250 Bought |
50,838 USD |
15/11/2024 | 19/11/2024 |
| Cueto Herman EX VP |
40.07 USD |
712 Sold |
28,530 USD |
19/11/2024 | 19/11/2024 |
| Zhou Ginger VP |
40.07 USD |
491 Sold |
19,674 USD |
19/11/2024 | 19/11/2024 |
| Madaus Martin D |
40.77 USD |
4,940 Bought |
201,404 USD |
19/11/2024 | 19/11/2024 |
| Wang David Dong VP |
40.07 USD |
348 Sold |
13,944 USD |
19/11/2024 | 19/11/2024 |